Peng Xi, Zhang Hui-Ping
Department of Cardiology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730 Beijing, China.
Rev Cardiovasc Med. 2023 Feb 2;24(2):40. doi: 10.31083/j.rcm2402040. eCollection 2023 Feb.
Acute cardiorenal syndrome (CRS) is often observed in patients with acute kidney injury (AKI) in the cardiac intensive care unit and is reported to be associated with poor prognosis. Volume disorder or re-distribution, renin-angiotensin-aldosterone system activation, and neurohormonal and sympathetic nervous system activation have been suggested to be related to the occurrence of acute CRS. There is a lack of biomarkers that can identify changes in renal function in patients with acute CRS. Evidence-based medications are limited in the management of acute CRS in AKI. Therefore, we reviewed the epidemiology, pathophysiology, clinical assessment, and treatment of acute CRS in AKI.
急性心肾综合征（CRS）常见于心脏重症监护病房的急性肾损伤（AKI）患者，据报道其与不良预后相关。容量紊乱或再分布、肾素-血管紧张素-醛固酮系统激活以及神经激素和交感神经系统激活被认为与急性CRS的发生有关。目前缺乏能够识别急性CRS患者肾功能变化的生物标志物。在AKI合并急性CRS的治疗中，循证医学支持的药物有限。因此，我们对AKI合并急性CRS的流行病学、病理生理学、临床评估及治疗进行了综述。
